6533b82bfe1ef96bd128df4a

RESEARCH PRODUCT

Fractional exhaled nitric oxide is associated with more severe asthma

Maike WilkStefanie VoigtStephanie KornRoland BuhlLucia Lanz

subject

medicine.medical_specialtyAllergybiologybusiness.industrySevere asthmaAirway inflammationrespiratory systemImmunoglobulin Emedicine.diseaseGastroenterologySerum igerespiratory tract diseases03 medical and health sciences0302 clinical medicine030228 respiratory systemInterquartile rangeInternal medicineExhaled nitric oxidemedicinebiology.protein030212 general & internal medicinebusinessAsthma

description

Fractional exhaled nitric oxide (FeNO) levels are used as a marker of airway inflammation. The aim of the present work was to evaluate a possible relationship between FeNO and parameters of asthma control and severity in different asthma phenotypes. FeNO was evaluated in 200 asthma patients (37% male, mean age ± SD 54±15 years, 19% controlled (GINA), 30% treated with oral corticosteroids (OCS), median FEV1 (interquartile range) 2,05 L (1,49-2,70), 74% pred. (56-90%)), together with other asthma characteristics (lung function, asthma control, allergies, serum IgE, serum ECP, and blood eosinophils). Patients with poorly controlled asthma had significantly higher FeNO values (ACQ-5≥1.5 vs. 70% (36 ppb (16-62) vs. 24 ppb (13-45), p=0.012). Patients treated with oral corticosteroids as maintenance treatment had significantly higher FeNO values than patients not on OCS (38 ppb (23-60) vs. 24 ppb (13-50), p=0.005). There was no correlation between FeNO levels and IgE, allergies, ECP or eosinophils. In asthma, FeNO concentrations were associated with higher asthma severity as reflected by uncontrolled asthma, lower FEV1 and maintenance treatment with oral corticosteroids.

yearjournalcountryeditionlanguage
2018-09-15Monitoring Airway Disease
https://doi.org/10.1183/13993003.congress-2018.pa1099